Evidence map›Paper›PMID 26522332›Full record

ArticleThe Lancet. Oncology2015

Germline genetic variation in ETV6 and risk of childhood acute lymphoblastic leukaemia: a systematic genetic study.

Takaya Moriyama, Monika L Metzger, Gang Wu, Rina Nishii, Maoxiang Qian, Meenakshi Devidas, Wenjian Yang, Cheng Cheng, Xueyuan Cao, Emily Quinn and 22 more

Registry-linked trialOpen access · greenAbstract read
In one paragraph

Article in The Lancet. Oncology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT00137111 (Total XV - Total Therapy Study XV for Newly Diagnosed Patients With Acute Lymphoblastic Leukemia), which is not on this map. Cited by 112 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
112citing papers in PubMed, 1 pooled it
18.9field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT00137111 phase3completednot on this map

Total XV - Total Therapy Study XV for Newly Diagnosed Patients With Acute Lymphoblastic Leukemia

TypeinterventionalSponsorSt. Jude Children's Research HospitalRan2000 to 2014Enrolled501ConditionsLymphoblastic Leukemia, AcuteArmsPrednisone, Dexamethasone, Vincristine, Daunorubicin, Doxorubicin, L-asparaginase, PEG-L-asparaginase, Erwinia asparaginase, Methotrexate, Cyclophosphamide, Cytarabine, Etoposide, Mercaptopurine, Imatinib, chemotherapy, intrathecal chemotherapy
3 · Its place in the literature

Who cites it

112 citing papers in PubMed, 1 synthesis or guideline pooled it, 206 citations in OpenAlex.

  1. A Systematic Literature Review of Whole Exome and Genome Sequencing Population Studies of Genetic Susceptibility to Cancer.Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology · 2020
    Pooled it
  2. Trial
  3. Trial
  4. Trial
  5. A GermlineEJHaem · 2026
    Article
  6. Article
  7. Article
  8. Article
  9. Review
  10. Article
  11. Review
  12. Review
  13. Review
  14. Article
  15. Review
  16. Biomedicines · 2025
    Review
  17. Article
  18. Article
  19. Review
  20. Mycovirus-ContainingInternational journal of molecular sciences · 2024
    Article

52 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

32 authors at 14 institutions in 3 countries.

Takaya MoriyamaDepartment of Pharmaceutical Sciences, St Jude Children's Research Hospital, Memphis, TN, USA; Department of Pediatrics, Mie University Graduate School of Medicine, Mie, Japan.
Monika L MetzgerDepartment of Oncology, St Jude Children's Research Hospital, Memphis, TN, USA.
Gang WuDepartment of Computational Biology, St Jude Children's Research Hospital, Memphis, TN, USA.
Rina NishiiDepartment of Pharmaceutical Sciences, St Jude Children's Research Hospital, Memphis, TN, USA; Department of Pediatrics and Developmental Biology, Tokyo Medical and Dental University Graduate School of Medicine, Tokyo, Japan.
Maoxiang QianDepartment of Pharmaceutical Sciences, St Jude Children's Research Hospital, Memphis, TN, USA.
Meenakshi DevidasDepartment of Biostatistics, College of Medicine, Public Health and Health Professions, University of Florida, Gainesville, FL, USA.
Wenjian YangDepartment of Pharmaceutical Sciences, St Jude Children's Research Hospital, Memphis, TN, USA.
Cheng ChengDepartment of Biostatistics, St Jude Children's Research Hospital, Memphis, TN, USA.
Xueyuan CaoDepartment of Biostatistics, St Jude Children's Research Hospital, Memphis, TN, USA.
Emily QuinnDepartment of Oncology, St Jude Children's Research Hospital, Memphis, TN, USA.
Susana RaimondiDepartment of Pathology, St Jude Children's Research Hospital, Memphis, TN, USA.
Julie M Gastier-FosterDepartment of Pathology and Laboratory Medicine, Nationwide Children's Hospital, and Departments of Pathology and Pediatrics, Ohio State University, Columbus, OH, USA.
Elizabeth RaetzHuntsman Cancer Institute, University of Utah, Salt Lake City, Utah, USA.
Eric LarsenMaine Children's Cancer Program, Scarborough, ME, USA.
Paul L MartinDepartment of Pediatrics, Duke University, Durham, NC, USA.
W Paul BowmanCook Children's Medical Center, Fort Worth, TX, USA.
Naomi WinickPediatric Hematology Oncology, University of Texas Southwestern Medical Center, Dallas, TX, USA.
Yoshihiro KomadaDepartment of Pediatrics, Mie University Graduate School of Medicine, Mie, Japan.
Shuoguo WangDepartment of Computational Biology, St Jude Children's Research Hospital, Memphis, TN, USA.
Michael EdmonsonDepartment of Computational Biology, St Jude Children's Research Hospital, Memphis, TN, USA.
Heng XuDepartment of Laboratory Medicine, National Key Laboratory of Biotherapy/Collaborative Innovation Center of Biotherapy and Cancer Center, West China Hospital, Sichuan University, Chengdu, China.
Elaine MardisMcDonnell Genome Institute, Washington University School of Medicine, St Louis, MO, USA.
Robert FultonMcDonnell Genome Institute, Washington University School of Medicine, St Louis, MO, USA.
Ching-Hon PuiDepartment of Oncology, St Jude Children's Research Hospital, Memphis, TN, USA; Department of Pathology, St Jude Children's Research Hospital, Memphis, TN, USA; Hematological Malignancies Program, Comprehensive Cancer Center, St Jude Children's Research Hospital, Memphis, TN, USA.
Charles MullighanDepartment of Pathology, St Jude Children's Research Hospital, Memphis, TN, USA; Hematological Malignancies Program, Comprehensive Cancer Center, St Jude Children's Research Hospital, Memphis, TN, USA.
William E EvansDepartment of Pharmaceutical Sciences, St Jude Children's Research Hospital, Memphis, TN, USA; Hematological Malignancies Program, Comprehensive Cancer Center, St Jude Children's Research Hospital, Memphis, TN, USA.
Jinghui ZhangDepartment of Computational Biology, St Jude Children's Research Hospital, Memphis, TN, USA.
Stephen P HungerDepartment of Pediatrics and Center for Childhood Cancer Research, Children's Hospital of Philadelphia and University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA.
Mary V RellingDepartment of Pharmaceutical Sciences, St Jude Children's Research Hospital, Memphis, TN, USA; Hematological Malignancies Program, Comprehensive Cancer Center, St Jude Children's Research Hospital, Memphis, TN, USA.
Kim E NicholsDepartment of Oncology, St Jude Children's Research Hospital, Memphis, TN, USA.
Mignon L LohDepartment of Pediatrics, Benioff Children's Hospital and Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, CA, USA.
Jun J YangDepartment of Pharmaceutical Sciences, St Jude Children's Research Hospital, Memphis, TN, USA; Hematological Malignancies Program, Comprehensive Cancer Center, St Jude Children's Research Hospital, Memphis, TN, USA. Electronic address: jun.yang@stjude.org.
St. Jude Children's Research Hospital · USJames S. McDonnell Foundation · USMie University · JPChildren's Hospital of Philadelphia · USCook Children's Medical Center · USDuke University · USNationwide Children's Hospital · USNew England Cancer Specialists · USSichuan University · CNThe University of Texas Southwestern Medical Center · USTokyo Medical and Dental University · JPUCSF Benioff Children's Hospital · USUniversity of Florida · USUniversity of Utah · US

Funding

NCTN BIQSFP ANBL1531 (NRT)U10CA180886 · NCI · PUBLIC HEALTH INSTITUTE · PI Douglas S. Hawkins · 2014 to 2026
$390.6M
COG FOREIGN ACCRUALU10CA098543 · NCI · NATIONAL CHILDHOOD CANCER FOUNDATION · PI ADAMSON, PETER C. · 2003 to 2013
$335.5M
Viral Vector Technology (VVTSR)P30CA021765 · NCI · ST. JUDE CHILDREN'S RESEARCH HOSPITAL · PI CHARLES ROBERTS · 1985 to 2026
$166.9M
COG SDMC - Statistics CoreU10CA180899 · NCI · UNIVERSITY OF SOUTHERN CALIFORNIA · PI TODD A ALONZO · 2014 to 2026
$132.8M
Children's Oncology Group Statistics &Data Center GrantU10CA098413 · NCI · UNIVERSITY OF NEBRASKA MEDICAL CENTER · PI DEVIDAS, MEENAKSHI · 2003 to 2013
$67.5M
CPML - Project 3: Genome-wide Studies of Adverse EffectsP50GM115279 · NIGMS · ST. JUDE CHILDREN'S RESEARCH HOSPITAL · PI LOH, MIGNON LEE-CHEUN, RELLING, MARY V · 2015 to 2019
$15.1M
Support for Human Specimen Banking in NCI-Supported Cancer Clinical TrialsU24CA114766 · NCI · RESEARCH INST NATIONWIDE CHILDREN'S HOSP · PI RAMIREZ MILAN, NILSA DEL CARMEN · 2005 to 2014
$14.5M
PAARK4Kids-Pharmacogenomics of Anticancer Agents Research in ChildrenU01GM092666 · NIGMS · ST. JUDE CHILDREN'S RESEARCH HOSPITAL · PI RELLING, MARY V · 2010 to 2014
$8.9M
NEXT GENERATION SEQUENCING ADD-ON-PHARMACOGENOMICS RESEARCH NETWROK (PGRN)U01GM097119 · NIGMS · WASHINGTON UNIVERSITY · PI MARDIS, ELAINE R · 2010 to 2014
$2.6M
NCI NIH HHS CA114766NCI NIH HHS CA180886NCI NIH HHS CA180899NCI NIH HHS CA21765NCI NIH HHS CA98413NCI NIH HHS CA98543NCI NIH HHS P30 CA021765NCI NIH HHS U10 CA098413NCI NIH HHS U10 CA098543NCI NIH HHS U10 CA180886NCI NIH HHS U10 CA180899NCI NIH HHS U24 CA114766NIGMS NIH HHS GM097119NIGMS NIH HHS GM115279NIGMS NIH HHS GM92666NIGMS NIH HHS P50 GM115279NIGMS NIH HHS U01 GM092666NIGMS NIH HHS U01 GM097119
6 · The paper itself

Abstract

backgroundHereditary predisposition is rarely suspected for childhood acute lymphoblastic leukaemia (ALL). Recent reports of germline ETV6 variations associated with substantial familial clustering of haematological malignancies indicated that this gene is a potentially important genetic determinant for ALL susceptibility. Our aims in this study were to comprehensively identify ALL predisposition variants in ETV6 and to determine the extent to which they contributed to the overall risk of childhood ALL.

methodsWhole-exome sequencing of an index family with several cases of ALL was done to identify causal variants for ALL predisposition. Targeted sequencing of ETV6 was done in children from the Children's Oncology Group and St Jude Children's Research Hospital front-line ALL trials. Patients were included in this study on the basis of their enrolment in these clinical trials and the availability of germline DNA. ETV6 variant genotypes were compared with non-ALL controls to define ALL-related germline risk variants. ETV6 variant function was characterised bioinformatically and correlated with clinical and demographic features in children with ALL.

findingsWe identified a novel non-sense ETV6 variant (p.Arg359X) with a high penetrance in an index family. Subsequent targeted sequencing of ETV6 in 4405 childhood ALL cases identified 31 exonic variants (four non-sense, 21 missense, one splice site, and five frameshift variants) that were potentially related to ALL risk in 35 cases (1%). 15 (48%) of 31 ALL-related ETV6 variants clustered in the erythroblast transformation specific domain and were predicted to be highly deleterious. Children with ALL-related ETV6 variants were significantly older at leukaemia diagnosis than those without (10·2 years [IQR 5·3-13·8] vs 4·7 years [3·0-8·7]; p=0·017). The hyperdiploid leukaemia karyotype was highly over-represented in ALL cases harbouring germline ETV6 risk variants compared with the wild-type group (nine [64%] of 14 cases vs 538 [27%] of 2007 cases; p=0·0050).

interpretationOur findings indicated germline ETV6 variations as the basis of a novel genetic syndrome associated with predisposition to childhood ALL. The development of recommendations for clinical interventions and surveillance for individuals harbouring ALL-related ETV6 variants are needed.

fundingUS National Institutes of Health and American Lebanese Syrian Associated Charities.

Indexed as

Germ-Line MutationAdolescentAge FactorsBiomarkers, TumorCase-Control StudiesChildChild, PreschoolComputational BiologyDatabases, GeneticDNA Mutational AnalysisETS Translocation Variant 6 ProteinExomeFemaleGene FrequencyGenetic Association StudiesGenetic Predisposition to DiseaseBiomarkers, TumorETS Translocation Variant 6 ProteinProto-Oncogene Proteins c-etsRepressor Proteins

Identifiers

PMID26522332
PMCPMC4684709
OpenAlexW1945175502

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.